



April 6, 2020

Via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Re: New Drug Introduction Report Pursuant to 18 V.S.A. § 4637(c)

To Whom It May Concern:

On March 18, 2020, and pursuant to 18 V.S.A. § 4637(b), Teva Pharmaceuticals USA, Inc. ("Teva") submitted a new drug introduction notice for the following (collectively, the "Product"):

NDC #	Product	WAC	Commercial Launch Date
63459-0303-43	HERZUMA® (trastuzumab-pkrb) 150 MG / 50 ML	\$1,402.50	03/16/2020
63459-0305-47	HERZUMA® (trastuzumab-pkrb) 420 MG / 10 ML	\$ 3,927.00	03/16/2020

Teva now provides the following additional information pursuant to 18 V.S.A. § 4637(c).


- 1. US and international marketing and pricing plans used at launch:** Teva declines to provide further information in accordance with 18 V.S.A. § 4637(d).
- 2. Estimated volume of patients:** Average of approximately 250 patients per month anticipated (in total, across both NDC's).
- 3. Whether the FDA granted breakthrough therapy designation or a priority review:** Neither
- 4. For drugs acquired:** Teva acquired rights on October 4, 2016 from Celltrion to commercialize HERZUMA® and another biosimilar product for \$160M in up-front payments plus additional payments dependent on product sales. The acquisition price for the HERZUMA® rights was incorporated into the broader deal's overall purchase price, and thus, there was no one particular price that Teva paid to acquire those rights.

* * * *



Teva provides this report consistent with its understanding and interpretation of 18 V.S.A. § 4637 and its provisions. In providing this report, Teva does not waive any rights that it may have at law or in equity with respect to 18 V.S.A. § 4637, its interpretation, and/or its application to Teva or any of its affiliates, now or in the future. Teva, on behalf of itself and affiliates, expressly reserves all such rights.

Sincerely,

DocuSigned by:

FB77687EB417471...

Jason Daly
SVP, US Market Access
Teva Pharmaceuticals USA, Inc.